GLP-1 drugs are now friendlier to needle-phobes. But do the pills still work?

The pharmacy benefit manager dropped Zepbound a year ago in favor of rival Wegovy — now both Lilly and Novo Nordisk drugs ...

For millions of people taking weight loss drugs, the next breakthrough may not be more weight loss.

CVS will add Zepbound coverage on Oct. 1, and start covering Lilly's newly approved Foundayo pill on June 1.

Mounjaro and Zepbound are two brand-name glucagon-like peptide-1 (GLP-1) medications manufactured by Eli Lilly. Although they contain the same active ingredient, tirzepatide, and may affect blood ...

This includes retatrutide, the GLP-1 injection that helped people lose 28% of their body weight in clinical trials Wegovy is the first GLP-1 approved for weight loss, but there are several new GLP-1 ...

CVS Caremark, one of America’s most powerful pharmacy benefit managers, will begin covering more GLP-1 medications again ...

By Amina Niasse NEW YORK, June 2 (Reuters) - Health insurer Cigna will stop covering GLP-1 weight-loss drugs including Novo ...

A new study is shedding light on which of two drugs currently approved by the U.S. Food and Drug Administration for weight loss is most effective at helping people lose more weight in less time.

CVS Health’s decision to expand formulary coverage for key GLP-1 therapies marks a boost for Eli Lilly's obesity drug ...

If you’re weighing the option of Wegovy versus Zepbound for weight loss, here’s how the two medications compare in terms of ...